INHERENT PROBLEMS with pd trials using brain surgery, page-2

Great comment old investor. The LCT narrative reads like a B Grade movie. A poor storyline (initial trial design), punctuated by less than desirable 'events' (results) all wrapped up in an understated and ineffective movie release process (marketing) with outdated performances by leading characters.....this is the LCT story we have seen play out across the years, the last two in particular. So what is next? More of the same rehashed narrative of 'wait and see', the same tired plot enacted by the overdrawn, weary and worrisome characters. And us - the watchers on, starring wide eyed at a repetitive (now boring and quite predictable) story line....

Or, we will see a bold, revitalised screen play that salvages the potential upside in the plot thus far, choosing to zoom in on the positive dimensions the trials have indeed achieved. A strong, refreshing narrative that inspires confidence, despite the pitfalls and speed bumps. In my opinion, the pattern of behaviour by the BoD to date unfortunately suggest not. Methinks that the greatest threat to LCT going forward is a lack of SH and market confidence. I think we are at a strategic (and practical) inflection point. Drastic action and decisions are now required. Yes, the statisticians will need to look at data, but what next. If the outcome is good, will this be subsumed in the ordinariness of the LCT marketing approach exhibited to date or simply lost in B grade business-as-usual? Confidence is not 'king', but it is a critical part of any business venture. Right now, I don't see any confidence anywhere. IMO, long time SHs are tired, expecting not much more than - more-of-the-same, same, same, same.... It is very, very sad that a company with so much promise, with great science minds and a spectacular vision of a medical paradigm change, seems intent on fading out of sight....